Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 9,926 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Terminated Phase 1Phase 2 Interventional Results available

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

NCT00981799
View directory record Official record
Conditions
Relapsed T-Cell Acute Lymphoblastic Leukemia, Relapsed T-Cell Lymphoblastic Lymphoma
Interventions
Nelarabine, Etoposide, Cyclophosphamide, Methotrexate, Filgrastim
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Surfactants on the Innate Immune System

NCT01951352
View directory record Official record
Conditions
Healthy
Interventions
Soap
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 30, 2026, 12:53 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Point-of-Care AI Assistance and Critical Care Outcomes: A Randomized Trial

NCT07293078
View directory record Official record
Conditions
Critical Illness, Sepsis, Acute Respiratory Failure (ARF), Multi-organ Failure, Acute Kidney Injury, Delirium Confusional State, Shock
Interventions
Point-of-care large language model decision support (ChatGPT-5)
Other
Lead sponsor
MetroWest Artificial Intelligence Research Workgroup
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Framingham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

It's WeWomen Plus Intervention for Health, Safety and Empowerment

NCT04098276
View directory record Official record
Conditions
Violence, Domestic, Violence-Related Symptom, Violence, Physical, Violence, Sexual, Violence, Gender-Based, Violence
Interventions
WeWomen Plus technology based intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
1,265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Photodynamic Therapy for Papulopustular Rosacea

NCT02075671
View directory record Official record
Conditions
Rosacea, Papulopustular Rosacea
Interventions
Aminolevulinic acid topical solution 20%, Blu-U Light Therapy, Placebo vehicle only
Drug · Device · Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 30, 2026, 12:53 AM EDT
Terminated Phase 1 Interventional

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

NCT03971734
View directory record Official record
Conditions
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Phase 1 Interventional

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

NCT02483247
View directory record Official record
Conditions
Cancer
Interventions
BBI503, Capecitabine, Doxorubicin, Nivolumab, Pembrolizumab, Paclitaxel, Sunitinib
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Fort Wayne, Indiana • Goshen, Indiana • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 30, 2026, 12:53 AM EDT
Suspended Phase 2 Interventional

UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

NCT03139747
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Lenvatinib, Everolimus
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 30, 2026, 12:53 AM EDT
Recruiting Phase 1 Interventional

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

NCT07172958
View directory record Official record
Conditions
Rhabdomyosarcoma, Ewing Sarcoma, Neuroblastoma, Wilms Tumor
Interventions
Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 23 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 12:53 AM EDT
Completed No phase listed Observational

Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

NCT05458258
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Myeloid
Interventions
Bioelectrical Impedence Analysis Device, 6 Minute Walk Test, Computed Tomography Scans to Measure Skeletal Muscular Index, Blood Test/Blood Draw, Hand Grip Strength Test
Device · Other · Diagnostic Test
Lead sponsor
University of Chicago
Other
Eligibility
60 Years and older
Enrollment
239 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Phase 2 Interventional

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)

NCT05996835
View directory record Official record
Conditions
Acute Kidney Injury Due to Sepsis
Interventions
TIN816 70 mg lyophilisate powder, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 30, 2026, 12:53 AM EDT
Withdrawn Not applicable Interventional

Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis

NCT01617798
View directory record Official record
Conditions
Respiratory Failure, Volume Overload, Hypernatremia
Interventions
Supplemental metolazone diuresis, Placebo Comparator: Control-- furosemide (lasix) only
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Intravenous Topiramate in Adult Patients

NCT00753493
View directory record Official record
Conditions
Epilepsy, Migraines
Interventions
intravenous topiramate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Not applicable Interventional

A Trial Assessing Chemo Mouthpiece Device With Best Supportive Care for Symptoms of Chemotherapy-Induced Oral Mucositis

NCT04595838
View directory record Official record
Conditions
Oral Mucositis
Interventions
Chemo Mouthpiece, Best Supportive Care only
Device · Other
Lead sponsor
Chemo Mouthpiece
Industry
Eligibility
18 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
11
States / cities
Costa Mesa, California • Goshen, Indiana • Farmington Hills, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Phase 1 Interventional

Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy

NCT02723448
View directory record Official record
Conditions
Vasculopathy, Retinal, With Cerebral Leukodystrophy, Cerebroretinal Vasculopathy, Hereditary
Interventions
aclarubicin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 30, 2026, 12:53 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Virtual Reality Versus Traditional Exercise on EMG Activity in Postural Malalignment

NCT07854678
View directory record Official record
Conditions
Postural Malalignment, Forward Head Posture, Rounded Shoulder Posture
Interventions
Virtual reality exercise, Active free Exercise
Other
Lead sponsor
Hofstra University
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Hempstead, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 12:53 AM EDT
Terminated Phase 4 Interventional Results available

Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients

NCT03743025
View directory record Official record
Conditions
Stress Hyperglycemia
Interventions
Dulaglutide Injection, Saline Injection
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
40 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

NCT05842967
View directory record Official record
Conditions
RESPIRATORY SYNCYTIAL VIRUS (RSV)
Interventions
RSVpreF, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma

NCT02949700
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Metformin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01846611
View directory record Official record
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions
Trabectedin, DOXIL, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Phase 3 Interventional

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis

NCT04102371
View directory record Official record
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal Saline, Plasma-lyte
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Months to 17 Years
Enrollment
9,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 30, 2026, 12:53 AM EDT
Completed Not applicable Interventional

Burden of Cancer in Children: A Pilot Study to Investigate the Impact and Content of Video Illness Narratives

NCT00793299
View directory record Official record
Conditions
Cancer
Interventions
Video Illness Narrative
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
10 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 30, 2026, 12:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 30, 2026, 12:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating AI-Generated Plain Language Summaries on Patient Comprehension of Ophthalmology Notes Among English-Speaking Patients

NCT06859216
View directory record Official record
Conditions
Ophthalmic Disease, Artifical Intelligence, Large Language Model
Interventions
AI-Generated Plain Language Summaries
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 30, 2026, 12:53 AM EDT